Related Experiment Video

Updated: Jun 8, 2026

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

Influence of statin therapy on circadian variation of acute myocardial infarction

Doğan Erdoğan1, Mehmet Ozaydın, Yasin Türker

  • 1Department of Cardiology, Medical Faculty, Süleyman Demirel University, Isparta, Turkey.

Anadolu Kardiyoloji Dergisi : AKD = the Anatolian Journal of Cardiology
|October 9, 2010
PubMed

Insights

Statin therapy does not alter the daily pattern of acute myocardial infarction (AMI) onset. This study found no significant difference in the circadian variation of AMI between patients taking statins and those not taking them.

Area of Science:

  • Cardiology
  • Chronobiology
  • Pharmacology

Background:

  • Circadian rhythms influence the timing of acute coronary events.
  • Medications like beta-blockers and ACE inhibitors can blunt the morning peak incidence of acute myocardial infarction (AMI).
  • The effect of statin therapy on the circadian variation of AMI remains unevaluated.

Purpose of the Study:

  • To investigate the influence of prior statin usage on the circadian variation of acute myocardial infarction (AMI).

Main Methods:

  • Retrospective analysis of 451 patients with ST-segment elevation AMI.
  • Patients were stratified into two groups: prior statin users and non-users.
  • Harmonic regression models were employed to assess circadian patterns of AMI onset.

Main Results:

  • A peak incidence of AMI was observed between 6:00 AM and 12:00 PM across all participants (OR 1.34).
  • Both statin and non-statin groups exhibited a morning peak in AMI incidence.
  • No statistically significant difference was found in the circadian variation of AMI between the statin and non-statin groups.

Conclusions:

  • Prior statin usage does not appear to influence the circadian periodicity of acute myocardial infarction (AMI).
  • Statin therapy did not blunt the characteristic morning peak incidence of AMI.
Abstract

Related Concept Videos

Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response01:15

Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response

Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...